Literature DB >> 3469276

Expression of MHC class II products on human colorectal cancer. An immunohistological and flow cytometric study.

M Moore, A K Ghosh, D Johnston, A J Street.   

Abstract

The MHC status of epithelial cells from 32 primary colorectal neoplasms, villous adenomata (VA; 2) and inflammatory bowel disease (IBD; 3) were evaluated using a panel of monoclonal antibodies (mAbs). Class I antigens and beta 2 microglobulin (beta 2m) were expressed on all normal, benign, inflammatory and malignant epithelia with the exception of two carcinomas. A more complex pattern of reactivity was encountered with anti-class II mAbs. Some expression was detected on normal glandular and luminal epithelium, particularly adjacent to the tumour. Inflammatory tissues, VA and 23/32 carcinomas were also antigen-positive, the proportion of stained epithelial cells ranging from 5% to 90%. Expression was usually non-coordinate, DR being the predominant specificity followed by DP and DQ, which is suggestive of independent D region gene regulation. The hypothesis that class II expression is induced in vivo by locally generated IFN gamma was not confirmed by in vitro treatment with this agent of epithelial colorectal carcinoma-derived cell lines. These provisional data suggest that although IFN gamma may be a necessary stimulus for class II expression it is insufficient and that other factors also influence the responsiveness of tumour cells in this respect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3469276     DOI: 10.1111/j.1744-313x.1986.tb01102.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  4 in total

1.  The relationship between epithelial Ia expression and the inflammatory cell infiltrate during experimental oral carcinogenesis.

Authors:  J B Matthews; A Pitigala-Arachchi; I J Crane; C Scully; S S Prime
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

2.  Heterogeneous epithelial expression of class II (HLA-DR) determinants and secretory component related to dysplasia in ulcerative colitis.

Authors:  T O Rognum; P Brandtzaeg; K Elgjo; O Fausa
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

3.  Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers.

Authors:  Elena Bolzacchini; Laura Libera; Sarah E Church; Nora Sahnane; Raffaella Bombelli; Nunzio Digiacomo; Monica Giordano; Guido Petracco; Fausto Sessa; Carlo Capella; Daniela Furlan
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

Review 4.  HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.

Authors:  Per Anderson; Natalia Aptsiauri; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 22.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.